263 related articles for article (PubMed ID: 25994549)
1. A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans.
Pleguezuelos O; Robinson S; Fernández A; Stoloff GA; Mann A; Gilbert A; Balaratnam G; Wilkinson T; Lambkin-Williams R; Oxford J; Caparrós-Wanderley W
Clin Vaccine Immunol; 2015 Jul; 22(7):828-35. PubMed ID: 25994549
[TBL] [Abstract][Full Text] [Related]
2. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial.
Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
Vaccine; 2012 Jun; 30(31):4655-60. PubMed ID: 22575166
[TBL] [Abstract][Full Text] [Related]
3. Meta-Analysis and Potential Role of Preexisting Heterosubtypic Cellular Immunity Based on Variations in Disease Severity Outcomes for Influenza Live Viral Challenges in Humans.
Pleguezuelos O; Robinson S; Fernandez A; Stoloff GA; Caparrós-Wanderley W
Clin Vaccine Immunol; 2015 Aug; 22(8):949-56. PubMed ID: 26084515
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.
van Doorn E; Pleguezuelos O; Liu H; Fernandez A; Bannister R; Stoloff G; Oftung F; Norley S; Huckriede A; Frijlink HW; Hak E
BMC Infect Dis; 2017 Apr; 17(1):241. PubMed ID: 28376743
[TBL] [Abstract][Full Text] [Related]
5. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.
Rudenko L; Kiseleva I; Stukova M; Erofeeva M; Naykhin A; Donina S; Larionova N; Pisareva M; Krivitskaya V; Flores J;
Vaccine; 2015 Sep; 33(39):5110-7. PubMed ID: 26296497
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults: A Randomized Clinical Trial.
Pleguezuelos O; Dille J; de Groen S; Oftung F; Niesters HGM; Islam MA; Næss LM; Hungnes O; Aldarij N; Idema DL; Perez AF; James E; Frijlink HW; Stoloff G; Groeneveld P; Hak E
Ann Intern Med; 2020 Apr; 172(7):453-462. PubMed ID: 32150750
[TBL] [Abstract][Full Text] [Related]
7. Assessment of CD8
Evans TG; Castellino F; Kowalik Dobczyk M; Tucker G; Walley AM; Van Leuven K; Klein J; Rutkowski K; Ellis C; Eagling-Vose E; Treanor J; van Baalen C; Filkov E; Laurent C; Thacker J; Asher J; Donabedian A
Lancet Microbe; 2024 Jul; 5(7):645-654. PubMed ID: 38729196
[TBL] [Abstract][Full Text] [Related]
8. A Dose-finding Study of a Wild-type Influenza A(H3N2) Virus in a Healthy Volunteer Human Challenge Model.
Han A; Czajkowski LM; Donaldson A; Baus HA; Reed SM; Athota RS; Bristol T; Rosas LA; Cervantes-Medina A; Taubenberger JK; Memoli MJ
Clin Infect Dis; 2019 Nov; 69(12):2082-2090. PubMed ID: 30770534
[TBL] [Abstract][Full Text] [Related]
9. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
Langley JM; Aoki F; Ward BJ; McGeer A; Angel JB; Stiver G; Gorfinkel I; Shu D; White L; Lasko B; Dzongowski P; Papp K; Alexander M; Boivin G; Fries L
Vaccine; 2011 Feb; 29(10):1921-8. PubMed ID: 21219987
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.
Aichinger G; Grohmann-Izay B; van der Velden MV; Fritsch S; Koska M; Portsmouth D; Hart MK; El-Amin W; Kistner O; Barrett PN
Clin Vaccine Immunol; 2015 Jan; 22(1):46-55. PubMed ID: 25355797
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study.
Hershberger E; Sloan S; Narayan K; Hay CA; Smith P; Engler F; Jeeninga R; Smits S; Trevejo J; Shriver Z; Oldach D
EBioMedicine; 2019 Feb; 40():574-582. PubMed ID: 30638863
[TBL] [Abstract][Full Text] [Related]
13. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine.
Vesikari T; Karvonen A; Korhonen T; Edelman K; Vainionpää R; Salmi A; Saville MK; Cho I; Razmpour A; Rappaport R; O'Neill R; Georgiu A; Gruber W; Mendelman PM; Forrest B;
Pediatr Infect Dis J; 2006 Jul; 25(7):590-5. PubMed ID: 16804427
[TBL] [Abstract][Full Text] [Related]
15. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.
Wacheck V; Egorov A; Groiss F; Pfeiffer A; Fuereder T; Hoeflmayer D; Kundi M; Popow-Kraupp T; Redlberger-Fritz M; Mueller CA; Cinatl J; Michaelis M; Geiler J; Bergmann M; Romanova J; Roethl E; Morokutti A; Wolschek M; Ferko B; Seipelt J; Dick-Gudenus R; Muster T
J Infect Dis; 2010 Feb; 201(3):354-62. PubMed ID: 20039806
[TBL] [Abstract][Full Text] [Related]
16. Selenium supplementation has beneficial and detrimental effects on immunity to influenza vaccine in older adults.
Ivory K; Prieto E; Spinks C; Armah CN; Goldson AJ; Dainty JR; Nicoletti C
Clin Nutr; 2017 Apr; 36(2):407-415. PubMed ID: 26803169
[TBL] [Abstract][Full Text] [Related]
17. The role of nasal IgA in children vaccinated with live attenuated influenza vaccine.
Ambrose CS; Wu X; Jones T; Mallory RM
Vaccine; 2012 Nov; 30(48):6794-801. PubMed ID: 23000125
[TBL] [Abstract][Full Text] [Related]
18. Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial.
Boffito M; Fox J; Bowman C; Fisher M; Orkin C; Wilkins E; Jackson A; Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
Vaccine; 2013 Nov; 31(48):5680-6. PubMed ID: 24120550
[TBL] [Abstract][Full Text] [Related]
19. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza.
Ramos EL; Mitcham JL; Koller TD; Bonavia A; Usner DW; Balaratnam G; Fredlund P; Swiderek KM
J Infect Dis; 2015 Apr; 211(7):1038-44. PubMed ID: 25281755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
